GC
ABCL icon

Guggenheim Capital’s AbCellera Biologics ABCL Stock Holding History

Guggenheim Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,362
Closed -$26.9K – 1680
2024
Q3 		$26.9K Sell
10,362
-922
-8% -$2.56K ﹤0.01% 1855
2024
Q2 		$33.4K Sell
11,284
-260
-2% -$984 ﹤0.01% 1852
2024
Q1 		$52.3K Sell
11,544
-194
-2% -$990 ﹤0.01% 1859
2023
Q4 		$67K Sell
11,738
-457
-4% -$2.12K ﹤0.01% 1861
2023
Q3 		$56.1K Buy
12,195
+283
+2% +$1.72K ﹤0.01% 1825
2023
Q2 		$77K Sell
11,912
-3,049
-20% -$20.8K ﹤0.01% 1846
2023
Q1 		$113K Buy
14,961
+4,337
+41% +$39.4K ﹤0.01% 1869
2022
Q4 		$108K Buy
+10,624
New +$123K ﹤0.01% 1866

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return